pelacarsen (AKCEA-APO(a)-LRx) - Novartis
HORIZON – Effect of Pelacarsen on Cardiovascular Outcomes in Patients With Elevated Lipoprotein(a): Primary Results From the Lp(a) HORIZON Trial (AHA 2026) - Oct 8, 2026 - Pres time: Nov 7, 2026; 08:45 AM - 08:55 AM; Location: Center Stage‚ North Hall‚ Level 3; In-Person; No abstract available 
Clinical • Late-breaking abstract • Cardiovascular
https://eppro01.ativ.me/web/page.php?page=session&project=AHA26&id=P16197
 
Michael Blaha; Hui Cao; Leslie Cho; Seth Frndak; Ioanna Gouni-Berthold; Ulf Landmesser; Eran Leitersdorf; Anastasia Lesogor; Abraham Lincoff; Brian Manning; Jackie McCluskey; Venu Menon; Ryuichi Morishita; Stephen Nicholls; Steven Nissen; Borge Nordestgaard; Raul Santos; Sotirios Tsimikas; Jing Wang; Kathy Wolski; Ziqiang Zhao
 
Oct 8, 2026
 
Prev Next